All Releases
 |
Aradigm Announces Private Placement for $5 Million
Jun 21, 2010
|
16.0 KB |
|
| |
HAYWARD, Calif., Jun 21, 2010 (BUSINESS WIRE) -- Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced that it
has entered into a definitive agreement for the sale of common stock and
warrants to three existing shareholders and one new investor in a
private placement for aggregate gross proceeds of approximately $...
|
|
Aradigm Presents at the 2010 International Conference of the American Thoracic Society
May 17, 2010
|
14.8 KB |
|
| |
HAYWARD, Calif., May 17, 2010 (BUSINESS WIRE) -- Aradigm Corporation (OTCBB: ARDM) ("the Company") today announced
it is presenting data on clinical trials with its ciprofloxacin for
inhalation formulations, ARD-3100 and ARD-3150, in healthy volunteers
and non-cystic fibrosis (CF) bronchiectasis (BE) patients at the 2010
...
|
|
Aradigm Announces First Quarter 2010 Financial Results
May 13, 2010
|
18.3 KB |
|
| |
HAYWARD, Calif., May 13, 2010 (BUSINESS WIRE) -- Aradigm Corporation (OTC BB: ARDM.OB) (the "Company") today
announced financial results for the first quarter and three months ended
March 31, 2010.
Total revenue was $4.0 million for the first quarter of 2010, compared
with zero revenue for the first quarter of 2009. Revenue...
|
|
Aradigm Receives FDA Clearance for Clinical Trial of Inhaled Liposomal Ciprofloxacin in Pediatric Patients With Cystic Fibrosis
May 5, 2010
|
15.7 KB |
|
| |
HAYWARD, Calif., May 05, 2010 (BUSINESS WIRE) -- Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced it
received clearance from the U.S. Food and Drug Administration (FDA) for
its inhaled liposomal ciprofloxacin Investigational New Drug (IND)
application. The first trial planned under this IND is a Phase 1/2a,
...
|
|
Aradigm Completes Enrollment and Doses Last Patient in Long Term Phase 2 Study of a Novel Inhaled Ciprofloxacin Formulation for the Management of Respiratory Infections in Bronchiectasis
Mar 25, 2010
|
14.8 KB |
|
| |
HAYWARD, Calif., Mar 25, 2010 (BUSINESS WIRE) -- Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced that
the last patient was enrolled and received the first dose in a 6-month,
multicenter, international Phase 2 clinical trial of a novel version of
inhaled ciprofloxacin (ARD-3150) in 40 adult patients with non-...
|
|
Aradigm Announces Fourth Quarter 2009 and Full Year Financial Results
Mar 23, 2010
|
21.1 KB |
|
| |
HAYWARD, Calif., Mar 23, 2010 (BUSINESS WIRE) -- Aradigm Corporation (OTC BB: ARDM.OB) (the "Company") today
announced financial results for the fourth quarter and full year ended
December 31, 2009.
The Company recorded no revenue in the fourth quarter of 2009 or the
fourth quarter of 2008. Total operating expenses for the ...
|
|
Aradigm Doses First Patient in Its Second Phase 2b Clinical Trial of Inhaled Liposomal Ciprofloxacin in Bronchiectasis Patients
Feb 23, 2010
|
15.1 KB |
|
| |
HAYWARD, Calif., Feb 23, 2010 (BUSINESS WIRE) -- Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced that it
dosed the first patient in the U.S. as part of its ORBIT-1 (Once-daily
Respiratory Bronchiectasis Inhalation Treatment) trial, an
international, randomized, double-blind, placebo-controlled Phase 2b
...
|
|
Aradigm Receives $4 Million Milestone Payment Upon First Commercial Sale of SUMAVEL* DosePro*
Feb 4, 2010
|
14.1 KB |
|
| |
HAYWARD, Calif., Feb 04, 2010 (BUSINESS WIRE) -- Aradigm Corporation (OTCBB:ARDM) (the "Company") announced today that it
received the $4 million milestone payment from Zogenix, Inc. ("Zogenix")
based upon the first commercial sale in the U.S. of SUMAVEL* DosePro*
(sumatriptan injection) needle-free delivery system. The Comp...
|
|
Aradigm to Present at Biotech Showcase 2010 on January 12
Jan 6, 2010
|
11.2 KB |
|
| |
HAYWARD, Calif., Jan 06, 2010 (BUSINESS WIRE) -- Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced that
President and Chief Executive Officer Igor Gonda, Ph.D., will present at
the Biotech Showcase 2010 on Tuesday, January 12, 2010, at 3:00 p.m.
Pacific time.
The event will be held at the Marines' Memorial Cl...
|
|
Aradigm to Present at the Lippert/Heilshorn Life Sciences Virtual Conference on December 15
Dec 10, 2009
|
11.9 KB |
|
| |
HAYWARD, Calif., Dec 10, 2009 (BUSINESS WIRE) -- Aradigm Corporation (OTCBB:ARDM) today announced that President and
Chief Executive Officer Igor Gonda, Ph.D. will present to investors as
part of the Lippert/Heilshorn & Associates Life Sciences On-line Forum
on December 15, 2009 at 12:00 Noon Eastern time.
Interested partie...
|
|
Aradigm Doses First Patient in Long-Term Phase 2 Study of a Novel Inhaled Ciprofloxacin Formulation for the Management of Respiratory Infections in Bronchiectasis
Nov 16, 2009
|
14.7 KB |
|
| |
HAYWARD, Calif., Nov 16, 2009 (BUSINESS WIRE) -- Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced that
the first patient was dosed in a 6-month, multicenter, international
Phase 2 clinical trial of a novel version of inhaled ciprofloxacin
(ARD-3150) in 40 adult patients with non-cystic fibrosis bronchiectasis...
|
|
Aradigm Announces Third Quarter 2009 Financial Results
Nov 5, 2009
|
19.4 KB |
|
| |
HAYWARD, Calif., Nov 05, 2009 (BUSINESS WIRE) -- Aradigm Corporation (OTCBB:ARDM) (the "Company")today
announced financial results for the third quarter and nine months ended
September 30, 2009 and recent highlights.
Revenue for the third quarter of 2009 was $4.9 million, compared to
revenue of $0.2 million for the third qu...
|
|
Aradigm to Present at the 8th Annual BIO Investor Forum on October 28
Oct 22, 2009
|
11.7 KB |
|
| |
HAYWARD, Calif., Oct 22, 2009 (BUSINESS WIRE) -- Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced that
President and Chief Executive Officer Igor Gonda, Ph.D., will present at
the 2009 Annual BIO Investor Forum on Wednesday, October 28, 2009, at
12:30 p.m. Pacific time (3:30 p.m. Eastern time).
The event wil...
|
|
Aradigm Presents Data Demonstrating Significant Antibacterial Concentrations and Effects in Non-Cystic Fibrosis Bronchiectasis Patients Following Administration of its Once-Daily Inhaled Liposomal Ciprofloxacin
Sep 14, 2009
|
14.3 KB |
|
| |
HAYWARD, Calif., Sep 14, 2009 (BUSINESS WIRE) -- Aradigm Corporation (OTCBB: ARDM) ("Aradigm") today announced it is
presenting data from its Phase 1 and Phase 2a studies at the ERS Annual
Congress in Vienna, Austria, September 12-16, 2009.
The first presentation describes the significant antibacterial
activity of CFI in th...
|
|
Aradigm Announces Second Quarter 2009 Financial Results
Aug 6, 2009
|
19.3 KB |
|
| |
HAYWARD, Calif., Aug 06, 2009 (BUSINESS WIRE) -- Aradigm Corporation (OTCBB: ARDM) (the "Company")today
announced financial results for the second quarter and six months ended
June 30, 2009.
No revenue was recorded for the second quarter of 2009, compared with
revenue of $54,000 for the second quarter of 2008. Research and ...
|
|
Aradigm Receives Orphan Drug Designation for Inhaled Liposomal Ciprofloxacin to Treat Cystic Fibrosis in Europe
Aug 5, 2009
|
13.4 KB |
|
| |
HAYWARD, Calif., Aug 05, 2009 (BUSINESS WIRE) -- Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced
that the European Medicines Agency (EMEA) granted Orphan Drug
Designation to the Company's inhaled liposomal ciprofloxacin drug
product candidate for the treatment of lung infections associated with
cysti...
|
|
Zogenix Announces Exclusive Co-Promotion Agreement in U.S. for Sumavel(TM) DosePro(TM)
Aug 4, 2009
|
12.2 KB |
|
| |
HAYWARD, Calif., Aug 04, 2009 (BUSINESS WIRE) -- Aradigm Corporation (OTCBB:ARDM) ("Aradigm") today announced that
Zogenix, Inc. ("Zogenix") and Astellas Pharma US, Inc. ("Astellas")
entered into an exclusive co-promotion agreement for the Sumavel DosePro
(sumatriptan injection) needle-free delivery system. Sumavel DosePro
...
|
|
Aradigm Receives FDA Clearance for Phase IIb Clinical Trial of Inhaled Liposomal Ciprofloxacin to Treat Bronchiectasis
Jul 23, 2009
|
15.0 KB |
|
| |
HAYWARD, Calif., Jul 23, 2009 (BUSINESS WIRE) -- Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced
it received clearance from the U.S. Food and Drug Administration (FDA)
for its inhaled liposomal ciprofloxacin Investigational New Drug (IND)
application. The initial clinical protocol under this IND is an
...
|
|
Zogenix Obtains Approval in U.S. for Sumavel(TM) DosePro(TM)
Jul 16, 2009
|
13.3 KB |
|
| |
HAYWARD, Calif., Jul 16, 2009 (BUSINESS WIRE) -- Aradigm Corporation (OTC BB: ARDM.OB) ("Aradigm") today announced
that Zogenix, Inc. was granted approval of the Sumavel(TM) DosePro(TM)
(sumatriptan injection) needle-free delivery system which enables
subcutaneous delivery of sumatriptan without a needle for the treatment
...
|
|
Aradigm Presents Phase 1 and Phase 2 Data on Inhaled Liposomal Ciprofloxacin in Healthy Volunteers and Cystic Fibrosis Patients at the 32nd European Cystic Fibrosis Conference
Jun 11, 2009
|
14.3 KB |
|
| |
HAYWARD, Calif., Jun 11, 2009 (BUSINESS WIRE) -- Aradigm Corporation (OTCBB:ARDM) ("Aradigm") today announced it is
presenting data from its Phase 1 study in healthy volunteers and Phase
2a study of inhaled liposomal ciprofloxacin in cystic fibrosis (CF)
patients at the 32nd European Cystic Fibrosis Conference in
Bre...
|
|
|
Press Releasese
